US Bancorp
ZVRA icon

US Bancorp’s Zevra Therapeutics ZVRA Stock Holding History

US Bancorp’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3K Sell
1,000
-34
-3% -$378 ﹤0.01% 3341
2026
Q1 		$9.64K Buy
1,034
+34
+3% +$306 ﹤0.01% 3375
2025
Q4 		$8.96K Hold
1,000
– – ﹤0.01% 3374
2025
Q3 		$9.51K Sell
1,000
-55
-5% -$552 ﹤0.01% 3330
2025
Q2 		$9.29K Buy
1,055
+42
+4% +$341 ﹤0.01% 3453
2025
Q1 		$7.59K Buy
1,013
+13
+1% +$103 ﹤0.01% 3528
2024
Q4 		$8.34K Hold
1,000
– – ﹤0.01% 3486
2024
Q3 		$6.94K Hold
1,000
– – ﹤0.01% 3474
2024
Q2 		$4.9K Hold
1,000
– – ﹤0.01% 3520
2024
Q1 		$5.8K Hold
1,000
– – ﹤0.01% 3490
2023
Q4 		$6.55K Buy
+1,000
New +$4.68K ﹤0.01% 3450

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

US Bancorp's ZVRA Position: Q2 2026 in Review

US Bancorp reduced its Zevra Therapeutics (ZVRA) stake by 3.3% in Q2 2026, selling an estimated $378 and leaving 1,000 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3341.

US Bancorp first reported a position in ZVRA in Q4 2023 and has held it in 11 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • US Bancorp held 1,000 shares of Zevra Therapeutics worth $14.3K as of Q2 2026.
  • US Bancorp sold 34 Zevra Therapeutics shares in Q2 2026, an estimated $378.
  • Zevra Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3341 holding.
  • US Bancorp first reported a position in Zevra Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.